Your browser doesn't support javascript.
loading
Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.
Rana, Huma Q; Stopfer, Jill E; Weitz, Michelle; Kipnis, Lindsay; Koeller, Diane R; Culver, Samantha; Mercado, Joanna; Gelman, Rebecca Sue; Underhill-Blazey, Meghan; McGregor, Bradley A; Sweeney, Christopher J; Petrucelli, Nancie; Kokenakes, Courtney; Pirzadeh-Miller, Sara; Reys, Brian; Frazier, Arthur; Knechtl, Andrew; Fateh, Salman; Vatnick, Donna Rachel; Silver, Rebecca; Kilbridge, Kerry E; Pomerantz, Mark M; Wei, Xiao X; Choudhury, Atish D; Sonpavde, Guru P; Kozyreva, Olga; Lathan, Christopher; Horton, Carrie; Dolinsky, Jill S; Heath, Elisabeth I; Ross, Theodora Suzanne; Courtney, Kevin Dale; Garber, Judy E; Taplin, Mary-Ellen.
Afiliación
  • Rana HQ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Stopfer JE; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA.
  • Weitz M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Kipnis L; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA.
  • Koeller DR; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Culver S; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA.
  • Mercado J; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA.
  • Gelman RS; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA.
  • Underhill-Blazey M; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA.
  • McGregor BA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Sweeney CJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Petrucelli N; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA.
  • Kokenakes C; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Pirzadeh-Miller S; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Reys B; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Frazier A; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Knechtl A; Karmanos Cancer Institute, Wayne State University, Detroit, MI.
  • Fateh S; Karmanos Cancer Institute, Wayne State University, Detroit, MI.
  • Vatnick DR; University of Texas Southwestern Medical Center, Dallas, TX.
  • Silver R; University of Texas Southwestern Medical Center, Dallas, TX.
  • Kilbridge KE; Karmanos Cancer Institute at McLaren Clarkston, Clarkston, MI.
  • Pomerantz MM; Karmanos Cancer Institute at McLaren Clarkston, Clarkston, MI.
  • Wei XX; Karmanos Cancer Institute at McLaren Clarkston, Clarkston, MI.
  • Choudhury AD; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA.
  • Sonpavde GP; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Kozyreva O; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Lathan C; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Horton C; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Dolinsky JS; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Heath EI; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Ross TS; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Courtney KD; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Garber JE; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Taplin ME; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
JCO Oncol Pract ; 19(11): 1069-1079, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37733980
ABSTRACT

PURPOSE:

Germline genetic testing (GT) is recommended for men with prostate cancer (PC), but testing through traditional models is limited. The ProGen study examined a novel model aimed at providing access to GT while promoting education and informed consent.

METHODS:

Men with potentially lethal PC (metastatic, localized with a Gleason score of ≥8, persistent prostate-specific antigen after local therapy), diagnosis age ≤55 years, previous malignancy, and family history suggestive of a pathogenic variant (PV) and/or at oncologist's discretion were randomly assigned 31 to video education (VE) or in-person genetic counseling (GC). Participants had 67 genes analyzed (Ambry), with results disclosed via telephone by a genetic counselor. Outcomes included GT consent, GT completion, PV prevalence, and survey measures of satisfaction, psychological impact, genetics knowledge, and family communication. Two-sided Fisher's exact tests were used for between-arm comparisons.

RESULTS:

Over a 2-year period, 662 participants at three sites were randomly assigned and pretest VE (n = 498) or GC (n = 164) was completed by 604 participants (VE, 93.1%; GC, 88.8%), of whom 596 participants (VE, 98.9%; GC, 97.9%) consented to GT and 591 participants completed GT (VE, 99.3%; GC, 98.6%). These differences were not statistically significant although subtle differences in satisfaction and psychological impact were. Notably, 84 PVs were identified in 78 participants (13.2%), with BRCA1/2 PV comprising 32% of participants with a positive result (BRCA2 n = 21, BRCA1 n = 4).

CONCLUSION:

Both VE and traditional GC yielded high GT uptake without significant differences in outcome measures of completion, GT uptake, genetics knowledge, and family communication. The increased demand for GT with limited genetics resources supports consideration of pretest VE for patients with PC.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Asesoramiento Genético Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans / Male / Middle aged Idioma: En Revista: JCO Oncol Pract Año: 2023 Tipo del documento: Article País de afiliación: Marruecos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Asesoramiento Genético Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans / Male / Middle aged Idioma: En Revista: JCO Oncol Pract Año: 2023 Tipo del documento: Article País de afiliación: Marruecos